18+

CELLIVITY / ADULT ACCESS

Are you 18 or older?

CELLIVITY is available to adults only. Supplement pages are general product information; peptide records are not a sales offer and are not for human use.

Age confirmation is a declaration, not identity verification. Restricted research access still requires separate professional eligibility checks.Privacy and legal notice ↗
Skip to content
CELLIVITY
Supplements
Peptides⌄
Research areasAll Peptides→Metabolic→Recovery→Nootropic→Energy→Aesthetics→Neuron→
Peptide calculatorAbout CELLIVITY
Featured productsRetatrutide฿3,700BPC-157฿1,300MOTS-c฿1,500GHK-Cu฿1,400
CalculatorScienceAbout Us
🇬🇧EN⌄
🇬🇧EnglishEN🇭🇺MagyarHU🇹🇭ไทยTH🇷🇺РусскийRU
Browse products ↗○LoginCart0
Supplements
Peptides+
All PeptidesMetabolicRecoveryNootropicEnergyAestheticsNeuronPeptide calculatorRetatrutide฿3,700BPC-157฿1,300MOTS-c฿1,500GHK-Cu฿1,400
Calculator↗ScienceAbout UsLogin / Create accountBrowse products
Currency
Thailand retail pricesProduct laboratory references18+ access
Peptides/Tesamorelin
Tesamorelin — CELLIVITYOpen full-size image ↗
Packaging concept; the selected format is shown below.Selected format: 10 mg
CELLIVITY PEPTIDE LABS · CEL-P-TES-001

Tesamorelin

Prescription peptide medicine; catalogue presentation remains unverified

For laboratory research only · Not intended for human or veterinary use.

Select format
THAILAND LAUNCH PRICE฿2,20010 mg · per vial · tax and delivery confirmed at enquiry
Sourced on enquiry · lead time confirmed individuallyAvailability is confirmed for this exact format before any commitment.
1
Selected10 mg · 1 vial · ฿2,200
Check availability ↗
Product reference filesQuality reviewThailand support
Product record
CEL-P-TES-001
Reference files
1 · CELLIVITY lot review pending
Product details ↓Lab documents (1) ↓Delivery ↓Check availability ↓
Lab documents

PRODUCT DESCRIPTION

Tesamorelin,
made legible.

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone. An authorised finished medicine exists in some markets for a narrow HIV-associated lipodystrophy indication; that does not make tesamorelin a general weight-loss or longevity product.

Research focus

GHRH-analogue biology in its defined clinical and research contexts.

Current evidence context

Controlled evidence and regulatory review apply to specific finished products and a defined indication. They cannot be transferred to general anti-ageing claims or to an unverified catalogue vial.

Questions this record follows

  • Which outcomes are specific to the authorised patient population?
  • How do endocrine and metabolic markers change during longer follow-up?
  • Which safety signals require continuing clinical monitoring?
Evidence boundaryAn approved narrow medical indication does not establish general longevity, recovery or weight-management use.

Follow the sources

Registry entries identify reference substances. Literature links describe research and do not certify this product or its batch.

  • Compound registryPubChem · CID 16137828 ↗

04 — LAB RESULTS & DOCUMENTS

One product. One place. One evidence trail.

Exact CELLIVITY-batch review is pending. Reference files below describe their own declared samples.

Purity, identity, per-vial content and sterility are separate results.

Product
Tesamorelin
Record
CEL-P-TES-001
Files received
1
Tesamorelin supplier certificate — original uploaded document
DOCUMENT RECEIVED · REVIEW PENDING

Tesamorelin supplier certificate

Supplier document declares 99.4% purity with RP-HPLC and MALDI-TOF methods.

Source
PepNexa supplier submission
Document type
Supplier certificate
Sample
Tesamorelin
Declared lot
PEPNEXA-2026-TES-0224
Report date
29 Jul 2026
Review state
Received — CELLIVITY review pending
Open original image ↗

AVAILABILITY

Tell us what
your lab needs.

Request current availability for a lawful institutional, analytical or laboratory purpose. We confirm the exact presentation, price, batch and document state before any next step.

  • Exact presentation review
  • Jurisdiction and purpose check
  • Batch-document confirmation
  • No medical or human-use guidance
SELECTED PRODUCTTesamorelinCEL-P-TES-001 · response after manual review

Tesamorelin · 10 mg × 1

Tesamorelin: before you enquire

What exactly does the selected format mean?+

The mg or IU value is the declared material content per vial; it is not the container volume. Your selected presentation and quantity are saved with your enquiry. The final price is confirmed in the response.

Which batch will be supplied?+

The specific batch and its documents are confirmed in the response. Files shown here may be supplier reference samples; the current record does not yet contain a qualified CELLIVITY lot dossier.

When can it arrive in Thailand?+

For confirmed local stock, the planned window is 2–3 working days in Thailand. Pattaya timing is agreed directly. Incoming or specially sourced products have a separate estimate, confirmed before a commitment.

Can I enquire about several products together?+

Yes. Add each format and quantity to the cart, then send one availability enquiry. Your selected items are kept together for review.

CELLIVITY

Tesamorelin

CEL-P-TES-001 · 10 mg

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone. An authorised finished medicine exists in some markets for a narrow HIV-associated lipodystrophy indication; that does not make tesamorelin a general weight-loss or longevity product.

GHRH-analogue biology in its defined clinical and research contexts.

Other names
TH9507 · TH 9507 · tesamorelin
PubChem CID
16137828
CAS number
218949-48-5
Molecular formula
C221H366N72O67S
Molecular weight
5136 g/mol
Peptide length
44 amino acids
Compound class
Synthetic growth-hormone-releasing-hormone analogue

Follow the sources

Controlled evidence and regulatory review apply to specific finished products and a defined indication. They cannot be transferred to general anti-ageing claims or to an unverified catalogue vial.

  • Which outcomes are specific to the authorised patient population?
  • How do endocrine and metabolic markers change during longer follow-up?
  • Which safety signals require continuing clinical monitoring?

Lab documents

CELLIVITY lot review pending

  • Tesamorelin supplier certificate · 29 Jul 2026 · PEPNEXA-2026-TES-0224

An approved narrow medical indication does not establish general longevity, recovery or weight-management use.

CELLIVITY · cellivity@gmail.com

← Back to collection
CELLIVITY

Your future is cellular.

SupplementsSupplementsPeptidesAbout Us
Product statusLaunch updatesLab document libraryPeptide dossier index
CELLIVITYAbout UsLanguagesSafetyContact
LegalMedical disclaimerPrivacyPrivacy request / unsubscribeTerms
Laboratory catalogue

18+ access. Peptide records support lawful laboratory enquiries only. Exact availability and lot documents are confirmed separately; no human or veterinary use instructions are provided.

Delivery, storage and responsibility

Delivery method, fees and the committed timeframe are set out in the accepted quotation. Delays or damage are handled with the recipient; CELLIVITY remains responsible for its agreed packaging and fulfilment. After receipt, the recipient must follow the documented storage conditions for the specific batch and report deviations. Research materials are intended for lawful work in an appropriate professional setting, not human or veterinary self-use. These terms do not exclude statutory liability or mandatory customer rights.

Full research-use terms →
© 2026 CELLIVITY. Pre-launch.Riviera Jomtien, 29/111, Pattaya 20150, ThailandControlled contact route

CELLIVITY / STAY IN THE LOOP

Follow the next
chapter.

New product records, laboratory documents and release news. Choose to hear from us when there is something useful to share.

  • New laboratory documents
  • Product availability updates
  • News from CELLIVITY
18+ only. Optional email updates. You can unsubscribe at any time.
Tesamorelin research dossier — CELLIVITY